Sanofi's innovative diabetes drug iGlarLixi China Phase III clinical trial reaches its primary efficacy endpoint

Shanghai, October 11, 2021/PRNewswire/ - Sanofi China announced at the 57th European Association for the Study of Diabetes (EASD) Annual Meeting that the company has developed a fixed-ratio combination of basal insulin and GLP-1RA in China SOLIQUA® (iGlarLixi)*'s phase III clinical study LixiLan-L China study reached the primary efficacy and secondary endpoints

The LixiLan-L China Study is a randomized, open-label, positive-controlled, parallel-grouped, 30-week clinical trial that aims to evaluate the efficacy and safety of iGlarLixi

The results of the LixiLan-L China study showed that compared with the basal insulin treatment group, patients treated with iGlarLixi reached the preset primary efficacy endpoint in reducing glycosylated hemoglobin (HbA1c)

The lead researcher of LixiLan-L in China, Professor Guo Xiaohui, Department of Endocrinology, Peking University First Hospital, said: “The results of this clinical trial confirm that patients with poor blood glucose control after treatment with basal insulin with or without up to two oral hypoglycemic drugs Compared with basal insulin, iGlarLixi is more effective and safer than basic insulin

Dr.

*SOLIQUA® (iGlarLixi) has not yet been approved in China

About Sanofi China

Sanofi is a leading global biopharmaceutical company focusing on human health

For more information, please visitor follow the "Sanofi China" WeChat official account and "Sanofi" LinkedIn account

About Sanofi

Sanofi is committed to helping people cope with health challenges

Sanofi has more than 100,000 employees in more than 100 countries and is committed to transforming scientific innovation into medical and health solutions

Sanofi, Empowering Life Sanofi, Empowering Life

Sanofi's forward-looking statements

This press release contains forward-looking statements

Source: Sanofi China